Jim Simons Scynexis Inc Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Scynexis Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 145,700 shares of SCYX stock, worth $193,781. This represents 0.0% of its overall portfolio holdings.

Number of Shares

145,700

Previous 139,000 4.82%

Holding current value

$193,781

Previous $278,000 21.94%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.27 - $2.23 $8,509 - $14,941	6,700 Added 4.82%	145,700 $217,000
Q2 2024 Aug 09, 2024	SELL	$1.4 - $2.77 $304,136 - $601,754	-217,240 Reduced 60.98%	139,000 $278,000
Q1 2024 May 13, 2024	BUY	$1.39 - $2.21 $174,167 - $276,913	125,300 Added 54.26%	356,240 $524,000
Q4 2023 Feb 13, 2024	BUY	$1.56 - $2.24 $275,652 - $395,808	176,700 Added 325.77%	230,940 $515,000
Q3 2023 Nov 14, 2023	SELL	$1.93 - $3.64 $263,136 - $496,277	-136,340 Reduced 71.54%	54,240 $124,000
Q2 2023 Aug 11, 2023	BUY	$2.38 - $3.67 $412,882 - $636,671	173,480 Added 1014.5%	190,580 $562,000
Q1 2023 May 12, 2023	BUY	$1.15 - $3.0 $7,014 - $18,300	6,100 Added 55.45%	17,100 $51,000
Q4 2022 Feb 13, 2023	BUY	$1.46 - $2.94 $16,060 - $32,340	11,000 New	11,000 $17,000
Q1 2021 May 13, 2021	SELL	$6.93 - $9.63 $897,060 - $1.25 Million	-129,446 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$4.28 - $7.87 $378,150 - $695,338	88,353 Added 215.01%	129,446 $990,000
Q3 2020 Nov 13, 2020	BUY	$4.37 - $7.48 $179,576 - $307,375	41,093 New	41,093 $181,000

Others Institutions Holding SCYX

# of Institutions

Shares Held

14.4M

Call Options Held

34K

Put Options Held

View Full List

About SCYNEXIS INC

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $43.4M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

More about SCYX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account